Insight

The first round of chemotherapy in high-risk neuroblastoma patients – St. Baldrick’s Foundation

Elizabeth Sokol/luriechildrens.org

Dec 27, 2024, 17:53

The first round of chemotherapy in high-risk neuroblastoma patients – St. Baldrick’s Foundation

St. Baldrick’s Foundation shared a post on LinkedIn about a recent paper by Elizabeth Sokol et al. published in EJC Paediatric Oncology:

“In high-risk neuroblastoma patients, their response to the first round of chemotherapy can provide doctors with valuable insights into their chances of recovery.

A recent study by the Children’s Oncology Group revealed that certain factors, such as the tumor’s origin and specific genetic changes, were associated with poorer outcomes in patients who didn’t respond well to treatment.

Conversely, patients who responded positively had fewer of these factors impacting their survival.”

“Response to induction chemotherapy modifies the effect of conventional prognostic factors in high-risk neuroblastoma: A report from the Children’s Oncology Group”

Authors: Elizabeth Sokol, Brian LaBarre, Navin Pinto, Susan Kreissman, Meaghan Granger, Julie Park, Rochelle Bagatell, Arlene Naranjo, Steven DuBois.

The first round of chemotherapy in high-risk neuroblastoma patients - St. Baldrick's Foundation

More posts featuring St. Baldrick’s Foundation.

Arlene Naranjo Brian LaBarre cancer Elizabeth Sokol Julie Park Meaghan Granger Navin Pinto neuroblastoma OncoDaily Oncology Rochelle Bagatell St. Baldrick's Foundation Steven DuBois Susan Kreissman

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial

John Cena Announces He Overcame Skin Cancer Twice, Advocates for Sun Safety

William N. Hait to Receive 2025 AACR-Margaret Foti Award for Leadership in Cancer Research